Related Experiment Videos
MCP-1 gene (SCYA2) and schizophrenia: a case-control association study
Emanuela Mundo1, A Carlo Altamura, Serena Vismara
1Department of Psychiatry, Department of Clinical Sciences Luigi Sacco, University of Milan, Via G.B. Grassi 74, 20157 Milan, Italy. emanuela.mundo@unimi.it
Summary
The SCYA2 gene
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Inflammation plays a role in schizophrenia.
- Monocyte chemoattractant protein 1 (MCP-1) is involved in immune responses.
- The SCYA2 gene's A-2518G polymorphism may affect MCP-1 production.
Purpose of the Study:
- To examine the SCYA2 A-2518G polymorphism's role in schizophrenia susceptibility.
- To investigate the polymorphism's association with antipsychotic treatment resistance.
Main Methods:
- A case-control study design was used.
- 191 schizophrenia patients and 161 healthy controls were analyzed.
- Genotyping for the SCYA2 A-2518G polymorphism was performed.
Main Results:
- No significant association was found between the SCYA2 A-2518G variant and schizophrenia diagnosis.
- A significant genotypic association was observed between the SCYA2 A-2518G variant and resistance to antipsychotic treatment.
- Patients resistant to antipsychotics were more likely to carry the G allele (OR=2.39).
Conclusions:
- The SCYA2 A-2518G variant is unlikely to be a major factor in schizophrenia development.
- This genetic variant may influence resistance to antipsychotic medications.